title: Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain.
abstract: Opioid analgesics are frequently prescribed and play an important role in chronic pain management. Opioid-induced bowel dysfunction, which includes constipation, hardened stool, incomplete evacuation, gas, and nausea and vomiting, is the most common adverse event associated with opioid use. Mu-opioid receptors are specifically responsible for opioid-induced bowel dysfunction, resulting in reduced peristaltic and secretory actions. Agents that reverse these actions in the bowel without reversing pain control in the central nervous system may be preferred over traditional laxatives. The efficacy and safety of these agents in chronic noncancer pain were assessed from publications identified through Ovid and PubMed database searches. Trials that evaluated the safety and efficacy of oral agents for opioid-induced constipation or opioid-induced bowel dysfunction, excluding laxatives, were reviewed. Lubiprostone and naloxegol are approved in the United States by the Food and Drug Administration for use in opioid-induced constipation. Axelopran (TD-1211) and sustained-release naloxone have undergone phase 2 and phase 1 studies, respectively, for the same indication. Naloxegol and axelopran are peripherally acting μ-opioid receptor antagonists. Naloxone essentially functions as a peripherally acting μ-opioid receptor antagonist when administered orally in a sustained-release formulation. Lubiprostone is a locally acting chloride channel (CIC-2) activator that increases secretions and peristalsis. All agents increase spontaneous bowel movements and reduce other bowel symptoms compared with placebo in patients with noncancer pain who are chronic opioid users. The most common adverse events were gastrointestinal in nature, and none of the drugs were associated with severe adverse or cardiovascular events. Investigations comparing these agents to regimens using standard laxative and combination therapy and trials in special populations and patients with active cancer are needed to further define their role in therapy.
authors.affiliation: Department of Medicine Section of Palliative Care, MedStar Washington Hospital Center, Washington, District of Columbia.
authors.forename: Renee M
authors.initials: RM
authors.lastname: Holder
authors.affiliation: College of Pharmacy, Roseman University of Health Sciences, Henderson, Nevada.
authors.forename: Diane
authors.initials: D
authors.lastname: Rhee
mesh_terms: D000284:Administration, Oral; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D059350:Chronic Pain / Q000188:drug therapy*; D003248:Constipation / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D000068238:Lubiprostone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009019:Morphinans / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
chemical_list: D000701:Analgesics, Opioid; D009019:Morphinans; D009292:Narcotic Antagonists; D017450:Receptors, Opioid, mu; D011092:Polyethylene Glycols; C000589308:naloxegol; D000068238:Lubiprostone
keywords: axelopran; lubiprostone; naloxegol; opioid-induced bowel dysfunction; opioid-induced constipation; peripherally acting μ-receptor antagonists; sustained release naloxone